Alnylam Pharmaceuticals (ALNY) is a publicly traded Healthcare sector company. As of August 19, 2026, ALNY trades at $230.51 with a market cap of $30.05B and a P/E ratio of 41.59. ALNY moved +1.81% today. Year to date, ALNY is -42.51%; over the trailing twelve months it is -49.96%. Its 52-week range spans $197.81 to $495.55. Analyst consensus is strong buy with an average price target of $369.33. Rallies surfaces ALNY's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies community data for ALNY shows anonymized retail investor ownership, positioning, sentiment, and portfolio context when enough community data is available.
| Metric | Value |
|---|---|
| Price | $230.51 |
| Market Cap | $30.05B |
| P/E Ratio | 41.59 |
| EPS | $5.53 |
| Dividend Yield | 0.00% |
| 52-Week High | $495.55 |
| 52-Week Low | $197.81 |
| Volume | 1.33M |
| Avg Volume | 0 |
| Revenue (TTM) | $4.80B |
| Net Income | $733.11M |
| Gross Margin | 79.79% |
19 analysts cover ALNY: 0 strong buy, 16 buy, 3 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $369.33.